Literature DB >> 26271606

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

S K Kumar1, E Ma2, A E Engebretson1, F K Buadi1, M Q Lacy1, A Dispenzieri1, M S Duh3, M-H Lafeuille3, P Lefebvre4, W Y Cheng3, K Dea4, D Rembert5, D Patt5, L Niculescu2, M Quick2, S V Rajkumar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26271606     DOI： 10.1038/leu.2015.225

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

Authors:  Shaji Kumar; Ian Flinn; Paul G Richardson; Parameswaran Hari; Natalie Callander; Stephen J Noga; A Keith Stewart; Francesco Turturro; Robert Rifkin; Jeffrey Wolf; Jose Estevam; George Mulligan; Hongliang Shi; Iain J Webb; S Vincent Rajkumar
Journal:  Blood       Date:  2012-03-15       Impact factor: 22.113

2.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

4.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Authors:  Shaji Kumar; Rafael Fonseca; Rhett P Ketterling; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; David Dingli; Ryan A Knudson; Alexandra Greenberg; Stephen J Russell; Steven R Zeldenrust; John A Lust; Robert A Kyle; Leif Bergsagel; S Vincent Rajkumar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

7.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

8.  Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.

Authors:  J G Gaultney; M G Franken; S S Tan; W K Redekop; P C Huijgens; P Sonneveld; C A Uyl-de Groot
Journal:  J Clin Pharm Ther       Date:  2012-11-06       Impact factor: 2.512

9.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

10.  Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.

Authors:  Maria Teresa Petrucci; Elisabetta Calabrese; Anna Levi; Vincenzo Federico; Michela Ceccolini; Rita Rizzi; Alessandro Gozzetti; Patrizia Falco; Carlo Lazzaro; Elisa Martelli; Mario Boccadoro; Francesco Lauria; Vincenzo Liso; Michele Cavo; Robert Foa
Journal:  Tumori       Date:  2013 Jul-Aug
View more
  4 in total

1.  Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Authors:  Nils Winkelmann; Max Desole; Inken Hilgendorf; Thomas Ernst; Herbert G Sayer; Christa Kunert; Lars-Olof Mügge; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

2.  Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.

Authors:  Surbhi Sidana; Shaji Kumar; Raphael Fraser; Noel Estrada-Merly; Sergio Giralt; Vaibhav Agrawal; Larry D Anderson; Mahmoud Aljurf; Rahul Banerjee; Asad Bashey; Minoo Battiwalla; Amer Beitinjaneh; Rajshekhar Chakraborty; Saurabh Chhabra; Binod Dhakal; Bhagirathbhai Dholaria; Shahrukh Hashmi; Murali Janakiram; Cindy Lee; Lazaros Lekakis; Hemant S Murthy; Ricardo Parrondo; Tamna Wangjam; Saad Usmani; Nina Shah; Muzaffar Qazilbash; Anita D'Souza
Journal:  Transplant Cell Ther       Date:  2021-11-12

Review 3.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

4.  Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.

Authors:  Shaji K Kumar; Francis K Buadi; Betsy LaPlant; Alese Halvorson; Nelson Leung; Prashant Kapoor; David Dingli; Morie A Gertz; Ronald S Go; P Leif Bergsagel; Yi Lin; Angela Dispenzieri; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Rafael Fonseca; Suzanne R Hayman; A Keith Stewart; John A Lust; Joseph Mikhael; Wilson Gonsalves; Craig Reeder; Tomas Skacel; S Vincent Rajkumar; Martha Q Lacy
Journal:  Blood Cancer J       Date:  2018-07-30       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.